Lipid Effects of Antihypertensive Medications

被引:10
作者
Deano, Roderick [1 ]
Sorrentino, Matthew [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Cardiol Sect, Dept Med, Chicago, IL 60637 USA
关键词
Hypertension; Dyslipidemia; Diabetes mellitus; Impaired glucose tolerance; Insulin resistance; Thiazide-induced diabetes; Beta-blockers; Calcium channel blockers (CCBs); Angiotensin converting enzyme (ACE) inhibitors; Angiotensin receptor blockers (ARBs); Renin-angiotensin-aldosterone system (RAAS); Alpha-1-antagonists; ASCOT; ACCOMPLISH; ALLHAT; TYPE-2; DIABETES-MELLITUS; INTIMA-MEDIA THICKNESS; BETA-BLOCKERS; INSULIN SENSITIVITY; CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; SERUM-LIPIDS; THERAPY; RISK; HYPERTENSION;
D O I
10.1007/s11883-011-0214-z
中图分类号
R6 [外科学];
学科分类号
100210 [外科学];
摘要
Thiazide diuretics and beta-blockers are first-line therapies for hypertension unless there are compelling indications for other drug classes. Diuretics and beta-blockers, however, may worsen dyslipidemia and glucose tolerance whereas antihypertensive agents in other drug classes may have neutral or beneficial effects. Initial clinical trials of antihypertensive regimens suggested that blood pressure lowering was the most important aspect of therapy and that the adverse effects on lipids and glucose tolerance did not impact clinical outcomes. Newer trials, however, question this finding and implicate these pleotropic effects as contributing to the results of the trials. Patients with cardiometabolic risk factors may have compelling indications for agents that inhibit the renin-angiotensin-aldosterone system, relegating diuretics and beta-blockers to third-line therapy.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 66 条
[1]
[Anonymous], 1991, JAMA, V265, P3255
[2]
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[3]
Lipophilic calcium antagonists in antiatherosclerotic therapy [J].
Bellosta S. ;
Bernini F. .
Current Atherosclerosis Reports, 2000, 2 (1) :76-81
[4]
Mechanism of differential effects of antihypertensive agents on serum lipids [J].
Brook R.D. .
Current Hypertension Reports, 2000, 2 (4) :370-377
[5]
Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? [J].
Chapman, Neil ;
Chen, Chung-Yin ;
Fujita, Toshiro ;
Hobbs, F. D. Richard ;
Kim, Soo-Joong ;
Staessen, Jan A. ;
Tanomsup, Supachai ;
Wang, Guang ;
Williams, Bryan .
JOURNAL OF HYPERTENSION, 2010, 28 (09) :1796-1803
[6]
Serum and Dietary Potassium and Risk of Incident Type 2 Diabetes Mellitus The Atherosclerosis Risk in Communities (ARIC) Study [J].
Chatterjee, Ranee ;
Yeh, Hsin-Chieh ;
Shafi, Tariq ;
Selvin, Elizabeth ;
Anderson, Cheryl ;
Pankow, James S. ;
Miller, Edgar ;
Brancati, Frederick .
ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (19) :1745-1751
[7]
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]
Are we misunderstanding beta-blockers [J].
Cruickshank, J. M. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 120 (01) :10-27
[9]
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis [J].
Elliott, William J. ;
Meyer, Peter M. .
LANCET, 2007, 369 (9557) :201-207
[10]
LIPIDS, LIPOPROTEINS, AND CORONARY HEART-DISEASE - IMPLICATIONS FOR ANTIHYPERTENSIVE THERAPY [J].
FEHER, MD ;
BETTERIDGE, DJ .
CARDIOVASCULAR DRUGS AND THERAPY, 1989, 3 :333-340